{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:22:37Z","timestamp":1791260557002,"version":"4.1.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Schizophrenia (SCZ) and treatment-resistant schizophrenia (TRS) are associated with aberrations in immune-inflammatory pathways. Increased high mobility group protein 1 (HMGB1), an inflammatory mediator, and Dickkopf-related protein (DKK1), a Wnt\/\u03b2-catenin signaling antagonist, affect the blood-brain barrier and induce neurotoxic effects and neurocognitive deficits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>The present study aims to examine HMGB1 and DDK1 in nonresponders to treatments (NRTT) with antipsychotics (n = 60), partial RTT (PRTT, n = 55), and healthy controls (n = 43) in relation to established markers of SCZ, including interleukin (IL)-6, IL-10, and CCL11 (eotaxin), and to delineate whether these proteins are associated with the SCZ symptom subdomains and neurocognitive impairments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HMGB1, DKK1, IL-6, and CCL11 were significantly higher in SCZ patients than in controls. DKK1 and IL-6 were significantly higher in NRTT than in PRTT and controls, while IL-10 was higher in NRTT than in controls. Binary logistic regression analysis showed that SCZ was best predicted by increased DDK1 and HMGB1, while NRTT (vs PRTT) was best predicted by increased IL-6 and CCL11 levels. A large part of the variance in psychosis, hostility, excitation, mannerism, and negative (PHEMN) symptoms and formal thought disorders was explained by HMGB1, IL-6, and CCL11, while most neurocognitive functions were predicted by HMGB1, DDK1, and CCL11.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The neurotoxic effects of HMGB1, DKK1, IL-6, and CCL11 including the effects on the blood-brain barrier and the Wnt\/\u03b2-catenin signaling pathway may cause impairments in executive functions and working, episodic, and semantic memory and explain, in part, PHEMN symptoms and a nonresponse to treatment with antipsychotic drugs.<\/jats:p><\/jats:sec>","DOI":"10.1093\/schbul\/sbaa136","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T11:10:47Z","timestamp":1598699447000},"page":"530-541","source":"Crossref","is-referenced-by-count":52,"title":["High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments"],"prefix":"10.1093","volume":"47","author":[{"given":"Arafat Hussein","family":"Al-Dujaili","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Kufa, Najaf, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Fadhil","family":"Mousa","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine, University of Kerbala, Kerbala, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein Kadhem","family":"Al-Hakeim","sequence":"additional","affiliation":[{"name":"Department of Chemistry, College of Science, University of Kufa, Najaf, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"},{"name":"Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria"},{"name":"IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"2021031702312397700_CIT0001","article-title":"Schizophrenia.","volume-title":"World Health Organization","author":"World Health Organization (WHO).","year":"2018"},{"key":"2021031702312397700_CIT0002","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0306-9877(95)90062-4","article-title":"The macrophage-T-lymphocyte theory of schizophrenia: additional evidence","volume":"45","author":"Smith","year":"1995","journal-title":"Med Hypotheses."},{"issue":"1","key":"2021031702312397700_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(96)02915-0","article-title":"Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs","volume":"66","author":"Maes","year":"1997","journal-title":"Psychiatry Res."},{"issue":"1","key":"2021031702312397700_CIT0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","article-title":"The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6","volume":"32","author":"Lin","year":"1998","journal-title":"Schizophr Res."},{"issue":"2","key":"2021031702312397700_CIT0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0924-977X(99)00062-0","article-title":"Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics","volume":"10","author":"Maes","year":"2000","journal-title":"Eur Neuropsychopharmacol."},{"issue":"3","key":"2021031702312397700_CIT0006","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr Res."},{"issue":"7","key":"2021031702312397700_CIT0007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry."},{"issue":"12","key":"2021031702312397700_CIT0008","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol Psychiatry."},{"key":"2021031702312397700_CIT0009","first-page":"4","article-title":"Effects of risperidone on cytokine profile in drug-na\u00efve first-episode psychosis","volume":"18","author":"Noto","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021031702312397700_CIT0010","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.psychres.2016.10.061","article-title":"Plasma levels of Th17-related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia","volume":"246","author":"Li","year":"2016","journal-title":"Psychiatry Res."},{"issue":"2","key":"2021031702312397700_CIT0011","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12640-019-00054-6","article-title":"Breakdown of the paracellular tight and adherens junctions in the gut and blood brain barrier and damage to the vascular barrier in patients with deficit schizophrenia","volume":"36","author":"Maes","year":"2019","journal-title":"Neurotox Res."},{"key":"2021031702312397700_CIT0012","doi-asserted-by":"crossref","DOI":"10.1007\/s12640-019-00112-z","article-title":"The neuro-immune fingerprint of major neuro-cognitive psychosis or deficit schizophrenia: a supervised machine learning study","author":"Al-Hakeim","year":"2020","journal-title":"Neurotox Res."},{"issue":"6","key":"2021031702312397700_CIT0013","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/15622975.2015.1062552","article-title":"High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance","volume":"16","author":"Noto","year":"2015","journal-title":"World J Biol Psychiatry."},{"issue":"2","key":"2021031702312397700_CIT0014","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12035-019-01737-z","article-title":"The role of aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia","volume":"57","author":"Roomruangwong","year":"2020","journal-title":"Mol Neurobiol."},{"key":"2021031702312397700_CIT0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1871527317666181119115532","article-title":"A new schizophrenia model: immune activation is associated with induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions","volume":"18","author":"Sirivichayakul","year":"2019","journal-title":"CNS Neurol Disord Drug Targets."},{"issue":"3","key":"2021031702312397700_CIT0016","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s12640-018-9987-y","article-title":"In schizophrenia, increased plasma IgM\/IgA responses to gut commensal bacteria are associated with negative symptoms, neurocognitive impairments, and the deficit phenotype","volume":"35","author":"Maes","year":"2019","journal-title":"Neurotox Res."},{"key":"2021031702312397700_CIT0017","doi-asserted-by":"crossref","DOI":"10.1080\/15622975.2019.1701203","article-title":"In schizophrenia, psychomotor retardation, with executive and memory impairments, negative and psychotic symptoms, neurotoxic immune products and lower natural IgM to malondialdehyde","volume-title":"World J Biol Psychiatry","author":"Maes","year":"2020"},{"key":"2021031702312397700_CIT0018","first-page":"20(9):747\u2013758","article-title":"Construction of a neuro-immune-cognitive pathway-phenotype underpinning the phenome of deficit schizophrenia. Curr Top Med Chem","author":"Al-Hakeim","year":"2020;"},{"key":"2021031702312397700_CIT0019","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12640-018-9937-8","article-title":"Eotaxin, an endogenous cognitive deteriorating chemokine (ECDC), is a major contributor to cognitive decline in normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and psychopathology in schizophrenia patients","volume":"35","author":"Sirivichayakul","year":"2019","journal-title":"Neurotox Res."},{"key":"2021031702312397700_CIT0020","doi-asserted-by":"crossref","first-page":"e85375","DOI":"10.1172\/jci.insight.85375","article-title":"Identification of CD163 as an anti-inflammatory receptor for HMGB1-haptoglobin complexes","volume":"1","author":"Yang","year":"2016","journal-title":"JCI Insight."},{"issue":"4","key":"2021031702312397700_CIT0021","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat Rev Immunol."},{"issue":"1","key":"2021031702312397700_CIT0022","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12974-016-0670-z","article-title":"HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer\u2019s disease","volume":"13","author":"Festoff","year":"2016","journal-title":"J Neuroinflammation."},{"issue":"2","key":"2021031702312397700_CIT0023","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.expneurol.2011.08.012","article-title":"High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products","volume":"232","author":"Mazarati","year":"2011","journal-title":"Exp Neurol."},{"key":"2021031702312397700_CIT0024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.diff.2019.05.003","article-title":"Dickkopf1: an immunomodulatory ligand and Wnt antagonist in pathological inflammation","volume":"108","author":"Chae","year":"2019","journal-title":"Differentiation."},{"key":"2021031702312397700_CIT0025","first-page":"162","article-title":"Wnts in action: from synapse formation to synaptic maintenance","volume":"5","author":"Dickins","year":"2013","journal-title":"Front Cell Neurosci."},{"issue":"12","key":"2021031702312397700_CIT0026","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/gerona\/glx252","article-title":"Circulating Dkk1 and TRAIL are associated with cognitive decline in community-dwelling, older adults with cognitive concerns","volume":"73","author":"Ross","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"1-3","key":"2021031702312397700_CIT0027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2010.01.014","article-title":"Genetic association study of KREMEN1 and DKK1 and schizophrenia in a Japanese population","volume":"118","author":"Aleksic","year":"2010","journal-title":"Schizophr Res."},{"issue":"11","key":"2021031702312397700_CIT0028","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol Psychiatry."},{"key":"2021031702312397700_CIT0029","first-page":"218","article-title":"Clinical Global Impressions","volume-title":"ECDEU Assessment Manual for Psychopharmacology\u2014Revised","author":"Guy","year":"1976"},{"key":"2021031702312397700_CIT0030","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr Bull."},{"key":"2021031702312397700_CIT0031","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000291496","article-title":"The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations","volume":"7","author":"Andreasen","year":"1989","journal-title":"Br J Psychiatry Suppl."},{"key":"2021031702312397700_CIT0032","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep."},{"key":"2021031702312397700_CIT0033","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"2","key":"2021031702312397700_CIT0034","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"issue":"2-3","key":"2021031702312397700_CIT0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr Res."},{"key":"2021031702312397700_CIT0036","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B (Methodol)."},{"issue":"5","key":"2021031702312397700_CIT0037","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1994.tb01527.x","article-title":"Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine","volume":"89","author":"Maes","year":"1994","journal-title":"Acta Psychiatr Scand."},{"issue":"3","key":"2021031702312397700_CIT0038","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.pnpbp.2007.11.019","article-title":"Increased serum levels of CCL11\/eotaxin in schizophrenia","volume":"32","author":"Teixeira","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"10","key":"2021031702312397700_CIT0039","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/embo-reports\/kvf198","article-title":"The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway","volume":"3","author":"Gardella","year":"2002","journal-title":"EMBO Rep."},{"issue":"1","key":"2021031702312397700_CIT0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1189\/jlb.0306172","article-title":"The maturation potential of NK cell clones toward autologous dendritic cells correlates with HMGB1 secretion","volume":"81","author":"Semino","year":"2007","journal-title":"J Leukoc Biol."},{"issue":"9","key":"2021031702312397700_CIT0041","doi-asserted-by":"crossref","first-page":"e0222369","DOI":"10.1371\/journal.pone.0222369","article-title":"HMGB1 mediates the development of tendinopathy due to mechanical overloading","volume":"14","author":"Zhao","year":"2019","journal-title":"PLoS One."},{"key":"2021031702312397700_CIT0042","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0074-7742(07)82007-1","article-title":"Relevance of high-mobility group protein box 1 to neurodegeneration","volume":"82","author":"Fossati","year":"2007","journal-title":"Int Rev Neurobiol."},{"issue":"4","key":"2021031702312397700_CIT0043","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.4049\/jimmunol.1103623","article-title":"Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation","volume":"189","author":"Lin","year":"2012","journal-title":"J Immunol."},{"issue":"19","key":"2021031702312397700_CIT0044","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2015-02-622233","article-title":"Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1\/VCAM-1-mediated neutrophilic acute lung inflammation","volume":"126","author":"Guo","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2021031702312397700_CIT0045","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/iid3.232","article-title":"Elevated blood levels of Dickkopf-1 are associated with acute infections","volume":"6","author":"Mazon","year":"2018","journal-title":"Immun Inflamm Dis."},{"issue":"2","key":"2021031702312397700_CIT0046","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ijc.30742","article-title":"Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro","volume":"141","author":"Zhang","year":"2017","journal-title":"Int J Cancer."},{"issue":"2","key":"2021031702312397700_CIT0047","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3325\/cmj.2016.57.89","article-title":"Interleukin 6\/Wnt interactions in rheumatoid arthritis: interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts","volume":"57","author":"Malysheva","year":"2016","journal-title":"Croat Med J."},{"issue":"3","key":"2021031702312397700_CIT0048","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.euroneuro.2018.12.008","article-title":"Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis","volume":"29","author":"Noto","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"issue":"3","key":"2021031702312397700_CIT0049","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12035-012-8264-y","article-title":"HMGB1 in development and diseases of the central nervous system","volume":"45","author":"Fang","year":"2012","journal-title":"Mol Neurobiol."},{"issue":"3","key":"2021031702312397700_CIT0050","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1523\/JNEUROSCI.3732-10.2011","article-title":"HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration","volume":"31","author":"Gao","year":"2011","journal-title":"J Neurosci."},{"key":"2021031702312397700_CIT0051","doi-asserted-by":"crossref","first-page":"31895","DOI":"10.1038\/srep31895","article-title":"HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer\u2019s disease","volume":"6","author":"Fujita","year":"2016","journal-title":"Sci Rep."},{"key":"2021031702312397700_CIT0052","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.neuroscience.2018.05.010","article-title":"HMGB1 neutralization attenuates hippocampal neuronal death and cognitive impairment in rats with chronic cerebral hypoperfusion via suppressing inflammatory responses and oxidative stress","volume":"383","author":"Hei","year":"2018","journal-title":"Neuroscience"},{"issue":"6","key":"2021031702312397700_CIT0053","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1159\/000489659","article-title":"HMGB1 a-box reverses brain edema and deterioration of neurological function in a traumatic brain injury mouse model","volume":"46","author":"Yang","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"2021031702312397700_CIT0054","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-030409-101323","article-title":"HMGB1 is a therapeutic target for sterile inflammation and infection","volume":"29","author":"Andersson","year":"2011","journal-title":"Annu Rev Immunol."},{"issue":"16","key":"2021031702312397700_CIT0055","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1001\/jama.2010.1553","article-title":"Long-term cognitive impairment and functional disability among survivors of severe sepsis","volume":"304","author":"Iwashyna","year":"2010","journal-title":"JAMA."},{"key":"2021031702312397700_CIT0056","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1146\/annurev.cellbio.20.010403.113126","article-title":"The Wnt signaling pathway in development and disease","volume":"20","author":"Logan","year":"2004","journal-title":"Annu Rev Cell Dev Biol."},{"issue":"3","key":"2021031702312397700_CIT0057","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1083\/jcb.200806024","article-title":"Wnt\/beta-catenin signaling controls development of the blood-brain barrier","volume":"183","author":"Liebner","year":"2008","journal-title":"J Cell Biol."},{"issue":"3","key":"2021031702312397700_CIT0058","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/jcbfm.2013.213","article-title":"The Wnt\/planar cell polarity signaling pathway contributes to the integrity of tight junctions in brain endothelial cells","volume":"34","author":"Artus","year":"2014","journal-title":"J Cereb Blood Flow Metab."},{"key":"2021031702312397700_CIT0059","doi-asserted-by":"crossref","first-page":"e43257","DOI":"10.7554\/eLife.43257","article-title":"Beta-catenin signaling regulates barrier-specific gene expression in circumventricular organ and ocular vasculatures","volume":"8","author":"Wang","year":"2019","journal-title":"eLife"},{"key":"2021031702312397700_CIT0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuint.2014.05.004","article-title":"Dysfunctional Wnt\/\u03b2-catenin signaling contributes to blood-brain barrier breakdown in Alzheimer\u2019s disease","volume":"75","author":"Liu","year":"2014","journal-title":"Neurochem Int."},{"key":"2021031702312397700_CIT0061","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2012.10.022","article-title":"The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia","volume":"48","author":"Na","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"5","key":"2021031702312397700_CIT0062","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/jnc.12492","article-title":"HIV increases the release of Dickkopf-1 protein from human astrocytes by a Cx43 hemichannel-dependent mechanism","volume":"128","author":"Orellana","year":"2014","journal-title":"J Neurochem."},{"issue":"2","key":"2021031702312397700_CIT0063","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nbd.2006.06.016","article-title":"Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1","volume":"24","author":"Scali","year":"2006","journal-title":"Neurobiol Dis."},{"issue":"2","key":"2021031702312397700_CIT0064","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.stem.2012.11.010","article-title":"Loss of Dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline","volume":"12","author":"Seib","year":"2013","journal-title":"Cell Stem Cell."},{"key":"2021031702312397700_CIT0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neubiorev.2019.10.019","article-title":"Influence of cognitive reserve in schizophrenia: a systematic review","volume":"108","author":"Herrero","year":"2020","journal-title":"Neurosci Biobehav Rev."},{"issue":"5","key":"2021031702312397700_CIT0066","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment \u2013 a review","volume":"39","author":"Marwaha","year":"2004","journal-title":"Soc Psychiatry Psychiatr Epidemiol."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/47\/2\/530\/36620729\/sbaa136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/47\/2\/530\/36620729\/sbaa136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T20:33:44Z","timestamp":1723494824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/47\/2\/530\/5911245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,24]]},"published-print":{"date-parts":[[2021,3,16]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbaa136","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,9,24]]}}}